Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
1-(C12-C18 even numbered, C18 unsaturated)alkyl-1,4,5,6-tetrahydropyrimidin-2-aminium acetate and{[3-((C12-C18 even numbered, C18 unsaturated)alkylamino)propyl]amino}(imino)methanaminium acetate and[(3-{[ammonio(imino)methyl]amino}propyl)(C12-C18 even numbered, C18 unsaturated)alkylamino](imino)methanaminium diacetate
EC number: 939-650-3 | CAS number: -
Endpoint summary
Administrative data
Link to relevant study record(s)
Description of key information
Data on the toxicokinetics of the registration substance are not available. However, toxicity data indicate that this compound and/or metabolites are absorbed from the gastro-intestinal tract. For structural related alkylguanidinium acetats (e.g 1-dodecylguanidinium acetate, n-dodecylguanidin hydrochloride) dermal penetration rates of about 50% have been demonstrated, which is assumed to be also valid for the registration substance. This view of limited dermal penetration of the registration substance is supported by the molecular weight (approximately 500) and log Pow of about 4 (in line with appendix R.7.12-4 of REACH endpoint guidance R7c) as well as by data from dermal toxicity studies with structural related alkylguanidinium acetates which revealed no specific systemic toxicity at doses which resulted in toxicity after oral administration. Therefore, a significant dermal absorption is not to be expected.
The reaction mass of the registration substance consists mainly of cocosalkyl mono- and cocosalkyl diguanidine derivatives. In accordance with the general metabolic scheme of such guanidine derivatives, at least two metabolic degradation pathways are conceivable with respect to the registration substance. This includes either the formation of a hydroxyalkylguanidine derivative via desamination and ω-oxidation which may be further degraded via ω- and ß-oxidation in mitochondria and/or lysosomes as well as the integration into catabolic pathways catalysed by ureohydrolases like arginase and agmatinase. Potential endproducts include acidic hydroxyalkylguanidine compounds, urea, CO2, as well as 1,3-diaminopropan. Published toxicological data revealed for the most common guanidine derivatives, i.e. dodecylguanidine acetate and dodecylguanidine hydrochloride, as well as the potential metabolic degradation products guanidine and diaminopropan are in good agreement with the available toxicity of the registration substance, which supports common toxicokinetics.
Key value for chemical safety assessment
- Absorption rate - oral (%):
- 100
- Absorption rate - dermal (%):
- 50
- Absorption rate - inhalation (%):
- 100
Additional information
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
